ReviewClinics in geriatric medicine2011
Clinical trials on sarcopenia: methodological issues regarding phase 3 trials.
Review in Clinics in geriatric medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.The journal of nutrition, health & aging · 2013Guideline
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).BMC geriatrics · 2025Observational
- Ultrasound Assessment of Sarcopenia in Alcoholic Liver Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Targeting Crosstalk of Signaling Pathways among Muscles-Bone-Adipose Tissue: A Promising Therapeutic Approach for Sarcopenia.Aging and disease · 2024Review
- New Scanographic Index for the Detection of Frailty in Patients with Cirrhosis with a Prognostic Impact.Middle East journal of digestive diseases · 2024Article
- Myosteatosis in Cirrhosis: A Review of Diagnosis, Pathophysiological Mechanisms and Potential Interventions.Cells · 2022Review
- Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults.Aging clinical and experimental research · 2021Review
- Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force.The Journal of frailty & aging · 2020Article
- Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2018Review
- Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort.Journal of musculoskeletal & neuronal interactions · 2017Article
- Selecting Potential Pharmacological Interventions in Sarcopenia.Drugs & aging · 2017Review
- Strength measures are better than muscle mass measures in predicting health-related outcomes in older people: time to abandon the term sarcopenia?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Reproducibility of jumping mechanography and traditional measures of physical and muscle function in older adults.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.Translational neuroscience · 2015Review
- Muscle changes in aging: understanding sarcopenia.Sports health · 2014Article
- Myostatin--the holy grail for muscle, bone, and fat?Current osteoporosis reports · 2013Review
- Frailty and sarcopenia: definitions and outcome parameters.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Review
- Sarcopenia: designing phase IIB trials.The journal of nutrition, health & aging · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Phase 3 trials estimate the effectiveness of an intervention to prevent, delay the onset of, or treat sarcopenia. Participants should have sarcopenia or present a sarcopenia risk profile. Control group should be characterized by the best standard of clinical care. This article further develops issues on sarcopenia definition, target population, primary and secondary end points, duration of the trials, muscle mass assessment, strength and physical performance assessment, and control of possible confounders. The challenges to conduct phase 3 trials in the elderly should not offset the opportunities for the development of new strategies to counteract sarcopenia and prevent late-life disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.